[ad_1]
This “Endometrial Cancer-Global Drug Forecast and Market Analysis to 2030” Report has been added to ResearchAndMarkets.com provide.
EC is a malignant tumor of the uterus. It is usually diagnosed in the early stages of the disease due to the common symptoms of postmenopausal bleeding. Due to the high rate of early diagnosis, surgery is the initial treatment option for patients, and only patients with a high risk of recurrence should consider adjuvant chemotherapy or hormone therapy. Due to the lack of treatment available for advanced and relapsed patients, patients who relapsed in the previous treatment have unmet needs related to EC. On the contrary, the guidelines recommend a large number of off-label therapies that have been shown to be beneficial to these patients but have not yet been approved.
As a result, these patients are further restricted by strict reimbursement regulations. Historically, EC has been classified as a hormone-driven or non-hormone-driven disease, but new biomarkers are being tested and approved in EC, which has led to the exploration of multiple pipeline drugs. The publisher predicts that a total of 5 new entrants will be launched during the 8MM forecast period from 2020 to 2030.
Main highlights
-
The main drivers of growth include the expected launch of new therapies, improved patient segmentation, the expected label expansion of market-leading drugs, and the increase in the incidence of 8MM disease.
-
The main obstacles to 8MM growth include patent expiration and strict reimbursement regulations for market-leading drugs, especially in Canada and Japan.
-
Among the pipeline products and marketing agents in the later stage, the combination immunotherapy of listed drugs is expected to generate the largest revenue during the forecast period.
-
The most important unmet needs in the EC market include the lack of approved therapies for advanced and relapsed patients, and the lack of patient segmentation after relapse.
Key question to answer
-
Starting in 2020, five late-stage pipeline agents and two label expansions will enter the EC market. What impact will these agents have on the market? Which of these drugs will have the highest sales peak and why?
-
What are the unmet needs of EC currently, and which pipeline agents can deal with these unmet needs? What are the R&D opportunities?
-
What is the market prospect of 8MM from 2020 to 2030? Taking into account the expiration of major patents, the introduction of new high-priced agents, and the expected label expansion.
range
-
EC outline, including epidemiology, etiology, pathophysiology, symptoms, diagnosis and treatment guidelines.
-
Revenue from the first-line EC market, annual treatment costs and sales of major pipeline products during the forecast period.
-
The key topics covered include current treatments and pipeline therapies, unmet needs and opportunities, and the drivers and barriers that affect the sales of EC therapies in 8MM.
-
Pipeline analysis: comprehensive data across different stages, emerging new trends under development, and detailed analysis of later pipeline drugs (stage three).
-
Analyze the current and future market competition in the global EC therapy market. An in-depth review of key industry drivers, constraints and challenges. Each trend has been independently studied to qualitatively analyze its impact.
Reasons to buy
-
Use a detailed overview of current pipeline products and technologies to determine the company with the most powerful pipeline to develop and design your internal and external licensing strategies.
-
Develop business strategies by understanding the trends shaping and driving the global EC treatment market.
-
Drive revenue by understanding key trends, innovative products and technologies, market segments, and companies that may affect the global e-commerce market in the future.
-
By understanding the competitive landscape and analyzing the performance of various competitors, formulate effective sales and marketing strategies.
-
Identify emerging players with potentially strong product portfolios and formulate effective countermeasures to gain a competitive advantage.
-
Track drug sales in the global EC therapy market from 2019 to 2029.
-
Organize your sales and marketing efforts by identifying market categories and market segments that provide the greatest opportunities for integration, investment, and strategic cooperation.
Companies mentioned
-
AstraZeneca
-
Eisai
-
Gene technology
-
GlaxoSmithKline
-
Kerry Medicine
-
Merck
-
Novartis
-
Pfizer
-
Roche
For more information about this report, please visit https://www.researchandmarkets.com/r/nnu5rf
View the source version on businesswire.com: https://www.businesswire.com/news/home/20210610005566/en/
[ad_2]
Source link
